Europe Rosacea Treatment Market Size & Outlook, 2025-2030
Related Markets
Europe rosacea treatment market highlights
- The Europe rosacea treatment market generated a revenue of USD 590.3 million in 2024.
- The market is expected to grow at a CAGR of 6.2% from 2025 to 2030.
- In terms of segment, antibiotics was the largest revenue generating drug class in 2024.
- Alpha agonists is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2025 to 2030.
Europe data book summary
| Market revenue in 2024 | USD 590.3 million |
| Market revenue in 2030 | USD 842.7 million |
| Growth rate | 6.2% (CAGR from 2025 to 2030) |
| Largest segment | Antibiotics |
| Fastest growing segment | Alpha agonists |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antibiotics, Alpha agonists, Retinoids, Corticosteroids, Immunosuppressants |
Other key industry trends
- In terms of revenue, Europe region accounted for 28.4% of the global rosacea treatment market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 842.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Rosacea Treatment Market Scope
Rosacea Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Aclaris Therapeutics | View profile | 101-250 | Malvern, Pennsylvania, United States, North America | http://www.aclaristx.com |
| Sol-Gel Technologies | View profile | 51-100 | Nes Ziyyona, HaMerkaz, Israel, Asia | http://www.sol-gel.com/ |
| Mayne Pharma Group Ltd | View profile | 160 | 1538 Main North Road, Salisbury South, Salisbury, SA, Australia, 5106 | http://www.maynepharma.com |
| Bausch Health Companies Inc | View profile | 20270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | https://www.bauschhealth.com |
| LEO Pharma | View profile | 1001-5000 | Parsippany, New Jersey, United States, North America | http://www.leo-pharma.us/ |
| Galderma Group AG Registered Shares | View profile | - | Zählerweg 10, Zug, Switzerland, 6300 | https://www.galderma.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Nestle SA | View profile | 270000 | Avenue Nestle 55, Vevey, Switzerland, CH-1800 | https://www.nestle.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
Europe rosacea treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rosacea treatment market will help companies and investors design strategic landscapes.
Antibiotics was the largest segment with a revenue share of 54.35% in 2024. Horizon Databook has segmented the Europe rosacea treatment market based on antibiotics, alpha agonists, retinoids, corticosteroids, immunosuppressants covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Europe rosacea treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe rosacea treatment market databook
-
Our clientele includes a mix of rosacea treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe rosacea treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Europe rosacea treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe rosacea treatment market size, by country, 2018-2030 (US$M)
Europe Rosacea Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
